Kimura A, Nakamura K, Makino I
Second Department of Internal Medicine, Asahikawa Medical College.
Nihon Shokakibyo Gakkai Zasshi. 1995 Mar;92(3):224-32.
Bile acid N-acetylglucosaminide (GlcNAc) was investigated in serum and urine of patients with chronic liver diseases during ursodeoxycholic acid (UDCA) treatment by HPLC. Bile acid N-acetylglucosaminide was not detected other than primary biliary cirrhosis in serum and urine. All of these N-acetyglucosaminide was ursodeoxycholic acid N-acetylglucosaminide (GlcNAc-UDCA). GlcNAc-UDCA excretion was 17.3 +/- 5.7 mg/day in PBC stage I, 12.1 +/- 5.4 mg/day in stage II, 39.1 +/- 20.8 mg/day in stage III. Among the GlcNAc fraction GlcNAc-UDCA-gly occupied greatest part followed by GlcNAc-UDCA-tau and non-amidated Glc-NAc-UDCA. GlcNAc-UDCA was 50.1% of total urinary bile acids excretion in PBC stage I, 32.5% in stage II, 20.5% in stage III. However, GlcNAc-UDCA was less than 2.5% of total serum bile acids in every stage. These results indicate that N-acetylglucosamine conjugation is one of the major pathway of UDCA in patient with primary biliary cirrhosis.
采用高效液相色谱法（HPLC）对慢性肝病患者在熊去氧胆酸（UDCA）治疗期间血清和尿液中的胆汁酸N - 乙酰葡糖胺（GlcNAc）进行了研究。除原发性胆汁性肝硬化患者的血清和尿液外，未检测到胆汁酸N - 乙酰葡糖胺。所有这些N - 乙酰葡糖胺均为熊去氧胆酸N - 乙酰葡糖胺（GlcNAc - UDCA）。在原发性胆汁性肝硬化I期，GlcNAc - UDCA排泄量为17.3±5.7mg/天；II期为12.1±5.4mg/天；III期为39.1±20.8mg/天。在GlcNAc组分中，GlcNAc - UDCA - gly占最大比例，其次是GlcNAc - UDCA - tau和非酰胺化的Glc - NAc - UDCA。在原发性胆汁性肝硬化I期，GlcNAc - UDCA占总尿胆汁酸排泄量的50.1%；II期为32.5%；III期为20.5%。然而，在各个阶段，GlcNAc - UDCA占总血清胆汁酸的比例均小于2.5%。这些结果表明，N - 乙酰葡糖胺结合是原发性胆汁性肝硬化患者中UDCA的主要代谢途径之一。
